Research Notes

Kodiak Sciences has reduced clinical uncertainty, but filing execution, regulatory review and capital demands now carry more of the evidence burden.

FormFactor’s growth, margin recovery and cash generation are improving, while a sharp share advance raises the evidence required for durability.

Applied Digital’s contracted footprint is substantial, but recurring rent, campus delivery and funding clarity will decide the quality of conversion.

Select Water Solutions pairs Pilot’s long-duration contracts with a cash-heavy deal, leaving financing and integration as the evidence test.

Summit Therapeutics pairs announced strategic backing with advancing clinical evidence, while financing, regulation, and execution remain decisive tests.

Warby Parker’s customer growth and improving profitability meet a harder test as intelligent eyewear launches without proven commercial economics.

RPM International enters its October earnings checkpoint with a record sales base, an operating-leverage outlook, and open questions around mix, costs, and cash discipline.

Akamai’s $11.6 billion cloud commitment puts delivery, capital intensity, margins, and cash conversion at the center of the next evidence test.

NetApp’s broad first-quarter growth meets a tougher cash-conversion test as a 14-week comparison raises the bar for evidence of lasting momentum.

NIKE enters October with wholesale growth, weaker direct demand, and blurred margin comparisons as investors look for a more durable turnaround signal.